Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles

Journal of Biomedical Informatics

Volumn 55, Issue , 2015, Pages 64-72

  Xu, Rong ^a   Wang, QuanQiu ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ThinTek LLC ^*  (United States)

Author keywords

Drug discovery; Drug repositioning; Drug side effects; Drug toxicity prediction; Information extraction; Targeted anticancer drugs; Text mining

Indexed keywords

CLASSIFICATION (OF INFORMATION); INFORMATION RETRIEVAL; KNOWLEDGE BASED SYSTEMS; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; POPULATION STATISTICS; SIGNAL PROCESSING; TEXT MINING; TOXICITY;

ANTICANCER DRUG; DRUG DISCOVERY; DRUG REPOSITIONING; DRUG SIDE EFFECTS; TOXICITY PREDICTIONS;

DRUG INTERACTIONS;

ALEMTUZUMAB; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; BOSUTINIB; CABOZANTINIB; CARFILZOMIB; CETUXIMAB; CRIZOTINIB; DASATINIB; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; IBRITUMOMAB TIUXETAN; IMATINIB; IPILIMUMAB; LAPATINIB; LETROZOLE; NILOTINIB; OFATUMUMAB; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PRALATREXATE; REGORAFENIB; UNINDEXED DRUG;

ARTICLE; AUTOMATION; BOOK; CANCER CONTROL; CLASSIFICATION; DRUG DATABASE; DRUG INDICATION; DRUG REPOSITIONING; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION RETRIEVAL; KNOWLEDGE BASE; MEDICAL INFORMATICS; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; SIDE EFFECT; SUPPORT VECTOR MACHINE; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CONTROLLED VOCABULARY; DATA MINING; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFORMATION PROCESSING; MACHINE LEARNING; MOLECULARLY TARGETED THERAPY; NATURAL LANGUAGE PROCESSING; ORGANIZATION AND MANAGEMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DATA MINING; DATASETS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MACHINE LEARNING; MOLECULAR TARGETED THERAPY; NATURAL LANGUAGE PROCESSING; PERIODICALS AS TOPIC; VOCABULARY, CONTROLLED;

EID: 84930713528     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2015.03.009     Document Type: Article

References (36)

1. Keefe D.M., Bateman E.H. Tumor control versus adverse events with targeted anticancer therapies. Nat. Rev. Clin. Oncol. 2011, 9(2):98-109.
2. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002, 346:645-652.
3. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
4. Reguart N., Cardona A.F., Rosell R. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. Cancer Manag. Res. 2010, 2:143-156.
5. Cleeland C.S., Allen J.D., Roberts S.A., Brell J.M., Giralt S.A., Khakoo A.Y., Kirch R.A., Kwitkowski V.E., Liao Z., Skillings J. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat. Rev. Clin. Oncol. 2012, 9:471-478.
6. Kirk R. Targeted therapies: the toxic reality of new drugs. Nat. Rev. Clin. Oncol. 2012, 9(9):488.
7. Niraula S., Seruga B., Ocana A., Shao T., Goldstein R., Tannock I.F., Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J. Clin. Oncol. 2012, 30(24):3012-3019.
8. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., Avkiran M., de Azambuja E., Balligand J., Brutsa D.L., Condorelli G., Hansen A., Heymans S., Hill J.A., Hirsch E., Hilfiker-Kleiner D., Janssens S., de Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P.H., Wojta J., Zannad F., Shah A.M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011, 13(1):1-10.
9. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 2010, 7(10):564-575.
10. Mellor H.R., Bell A.R., Valentin J.P., Roberts R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 2011, 120(1):14-32.
11. Bonura F., Di Lisi D., Novo S., D'Alessandro N. Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. Cardiovasc. Toxicol. 2012, 12(2):93-107.
12. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann. Oncol. 2009, 20(suppl. 1):i7-i12.
13. Davies M.A., Fox P.S., Papadopoulos N.E., Bedikian A.Y., Hwu W.J., Lazar A.J., Prieto V.G., Culotta K.S., Madden T.L., Xu Q., Huang S., Deng W., Ng C.S., Gupta S., Liu W., Dancey J.E., Wright J.J., Bassett R.L., Hwu P., Kim K.B. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin. Can. Res. 2012, 18(4):1120-1128.
14. Molina A.M., Feldman D.R., Voss M.H., Ginsberg M.S., Baum M.S., Brocks D.R., Fischer P.M., Trinos M.J., Patil S., Motzer R.J. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118(7):1868-1876.
15. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., Gunn S., Smetzer L., Mays T.A., Kaiser B., Wick M.J., Alvarez C., Cavazos A., Mangold G.L., Patnaik A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Can. Res. 2012, 18(8):2316-2325.
16. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
17. Cami A., Arnold A., Manzi S., Reis B. Predicting adverse drug events using pharmacological network models. Sci. Transl. Med. 2011, 3(114):114-127.
18. Campillos M., Kuhn M., Gavin A.C., Jensen L.J., Bork P. Drug target identification using side-effect similarity. Science 2008, 321(5886):263-266.
19. Duran-Frigola M., Aloy P. Recycling side-effects into clinical markers for drug repositioning. Genome Med. 2012, 4(3).
20. Hurle M.R., Yang L., Xie Q., Rajpal D.K., Sanseau P., Agarwal P. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Therapeut. 2013, 93(4):335-341.
21. Lounkine E., Keiser M.J., Whitebread S., Mikhailov D., Hamon J., Jenkins J.L., Layan P., Weber E., Doak A.K., Cote S., Shoichet B.K., Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012, 486(7403):361-367.
22. Seruga B., Sterling L., Wang L., Tannock I.F. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J. Clin. Oncol. 2011, 29:174-185.
23. R. Xu, Q. Wang, Automatic signal prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS), J. Biomed. Inform. (2014) 171-177.
24. Xu R., Wang Q. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. BMC Bioinf. 2014, 15:17. 10.1186/10.1186/1471-2105-15-17.
25. Xu R., Wang Q. Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug side effect relationships from literature. J. Am. Med. Inf. Assoc. 2014, 21(1):90-96.
26. R. Xu, Q. Wang, Automatic construction of a large-scale and accurate drug-side-effect association knowledge base from biomedical literature, J. Biomed. Inf. 51 (2014) 191-199.
27. R. Xu, Q. Wang, Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles, J. Biomed. Inf. 53 (2015) 128-135.
28. Xu R., Li L., Wang Q. Towards building a disease-phenotype knowledge base: extracting disease-manifestation relationship from literature. Bioinformatics 2013, 29(17):2186-2194.
29. Xu R., Li L., Wang Q. dRiskKB: a large-scale disease-disease risk (causal) relationship knowledge base constructed from biomedical text. BMC Bioinf. 2014, 15:105. 10.1186/1471-2105-15-105.
30. Gurulingappa H., Mateen Rajput A., Toldo L. Extraction of potential adverse drug events from medical case reports. J. Biomed. Semant. 2012, 3(1):15-24.
31. Brown E.G., Wood L., Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999, 20(2):109-117.
32. Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucl. Acids Res. 2004, 32(suppl. 1):D267-D270.
33. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. The WEKA data mining software: an update. ACM SIGKDD Explor. Newslett. 2009, 11(1):10-18.
34. Manning C.D., Raghavan P., Schutze H. Introduction to Information Retrieval 2008, vol. 1. Cambridge University Press, Cambridge.
35. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucl. Acids Res. 2008, 36(suppl. 1):D901-D906.
36. Tatonetti N.P., Patrick P.Y., Daneshjou R., Altman R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 2012, 4(125):125ra31.